Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata

    February 2026 in “ The Journal of Dermatology ”
    Rie Ueki, Masato Mizuashi, Kazutoshi Harada … Tomohiro Hirose
    Studysummary This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 12

    1. Efficacy And Safety Of Ritlecitinib In Asian Patients With Alopecia Areata: A Subgroup Analysis Of The ALLEGRO Phase 2b/3 Trial The Journal of Dermatology · 2025
    2. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    3. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    4. Long-Term Efficacy of Ritlecitinib Up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata SKIN The Journal of Cutaneous Medicine · 2024
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Prevalence, Comorbidities, and Treatment Patterns of Japanese Patients with Alopecia Areata: A Descriptive Study Using Japan Medical Data Center Claims Database The Journal of Dermatology · 2022
    7. The Epidemiology of Alopecia Areata: A Population-Based Cohort Study in UK Primary Care British Journal of Dermatology · 2021
    8. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States Clinical Cosmetic and Investigational Dermatology · 2020
    9. Treatment of Alopecia Areata: An Australian Expert Consensus Statement Australasian journal of dermatology · 2018
    10. Race and Alopecia Areata Amongst US Women Journal of Investigative Dermatology Symposium Proceedings · 2017
    11. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014
    12. Prevalence of Dermatological Disorders in Japan: A Nationwide, Cross-Sectional, Seasonal, Multicenter, Hospital-Based Study Journal of Dermatology · 2011